Results 31 to 40 of about 42,609 (234)

A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID‐19: Will cases of psoriasis increase after COVID‐19 pandemic?

Dermatologic Therapy, 2020
Dear Editor, COVID-19 pandemics have been described in the city of Wuhan in China and spread around the world. The new type of SARS-Cov2, a mutant novel coronavirus that humans encountered for the first time, binds to ACE receptors cause pneumonia ...
Ömer Kutlu, A. Metin
semanticscholar   +1 more source

Systematic review and meta-analysis of the efficacy and safety of oseltamivir (Tamiflu) in the treatment of Coronavirus Disease 2019 (COVID-19).

PLoS ONE, 2022
Efforts are ongoing by researchers globally to develop new drugs or repurpose existing ones for treating COVID-19. Thus, this led to the use of oseltamivir, an antiviral drug used for treating influenza A and B viruses, as a trial drug for COVID-19 ...
Basiru Aliyu, Yakubu Egigogo Raji, Hui-Yee Chee, Mui-Yun Wong, Zamberi Bin Sekawi   +4 more
doaj   +2 more sources

Tracking oseltamivir-resistance in New Zealand influenza viruses during a medicine reclassification in 2007, a resistant-virus importation in 2008 and the 2009 pandemic

Western Pacific Surveillance and Response, 2012
Introduction: Oseltamivir (Tamiflu®) is an important pharmaceutical intervention against the influenza virus. The importance of surveillance for resistance to oseltamivir has been highlighted by two global events: the emergence of an oseltamivir ...
Q Sue Huang, Jing Wang, Wendy Gunn, Molly Ziki, Mackenzie Nicol, Judy Bocacao, Jacqui C Ralston, Danielle J de Joux, Matthew Peacey, Richard J Hall   +9 more
doaj   +1 more source

Contact transmission of influenza virus between ferrets imposes a looser bottleneck than respiratory droplet transmission allowing propagation of antiviral resistance [PDF]

, 2016
Influenza viruses cause annual seasonal epidemics and occasional pandemics. It is important to elucidate the stringency of bottlenecks during transmission to shed light on mechanisms that underlie the evolution and propagation of antigenic drift, host ...
Ashcroft, J, Barclay, W, Bradley, K, Donnelly, C, Elderfield, R, Fernandez-Alonso, M, Frise, R, Galiano, M, Lackenby, A, Miah, S, Roberts, K, Stilwell, P, Van Doremalen, N   +12 more
core   +1 more source

Oseltamivir Enhances Hippocampal Network Synchronization

Journal of Pharmacological Sciences, 2008
Oseltamivir, a widely used anti-influenza drug, inhibits virus neuraminidase. A mammalian homologue of this enzyme is expressed in the brain, yet the effect of oseltamivir on central neurons is largely unknown.
Atsushi Usami, Takuya Sasaki, Nobuhiro Satoh, Takahiro Akiba, Satoshi Yokoshima, Tohru Fukuyama, Kenzo Yamatsugu, Motomu Kanai, Masakatsu Shibasaki, Norio Matsuki, Yuji Ikegaya   +10 more
doaj   +1 more source

Acute Cheilitis Associated with Oseltamivir after Influenzae A Infection

Case Reports in Pediatrics, 2023
Oseltamivir is a neuraminidase inhibitor used to treat acute influenza A or B in adult and pediatric patients. Adverse reactions are usually mild. Here, we report novel side effects associated with oseltamivir.
Koji Yokoyama, Mitsukazu Mamada
doaj   +1 more source

Characteristics of Patients with Oseltamivir-Resistant Pandemic (H1N1) 2009, United States

Emerging Infectious Diseases, 2011
During April 2009–June 2010, thirty-seven (0.5%) of 6,740 pandemic (H1N1) 2009 viruses submitted to a US surveillance system were oseltamivir resistant.
Samuel B. Graitcer, Larisa Gubareva, Laurie Kamimoto, Saumil Doshi, Meredith Vandermeer, Janice Louie, Christine Waters, Zack Moore, Katrina Sleeman, Margaret Okomo-Adhiambo, Steven A. Marshall, Kirsten St. George, Chao-Yang Pan, Jennifer M. LaPlante, Alexander Klimov, Alicia M. Fry   +15 more
doaj   +1 more source

Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children [PDF]

, 2014
BACKGROUND: Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies for treating and preventing seasonal and pandemic influenza. They are used clinically worldwide.
Del Mar, Chris B., Doshi, Peter, Hama, Rokuro, Heneghan, Carl J., Howick, Jeremy, Jefferson, Tom, Jones, Mark A., Mahtani, Kamal R., Nunan, David, Onakpoya, Igho, Spencer, Elizabeth A., Thompson, Matthew J.   +11 more
core   +1 more source

Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection.

Journal of Infectious Diseases, 2019
BACKGROUND A synergistic effect of combination therapy with favipiravir and oseltamivir has been reported in pre-clinical models of influenza. However, no data are available on the clinical effectiveness of combination therapy in severe influenza ...
Ye-ming Wang, Guohui Fan, A. Salam, P. Horby, F. Hayden, Cheng Chen, Jianguang Pan, Jing Zheng, B. Lu, Liping Guo, Chen Wang, B. Cao   +11 more
semanticscholar   +1 more source

The anti-influenza drug oseltamivir evokes hypothermia in mice through dopamine D2 receptor activation via central actions

Journal of Pharmacological Sciences, 2018
Oseltamivir has a hypothermic effect in mice when injected intraperitoneally (i.p.) and intracerebroventricularly (i.c.v.). Here we show that the hypothermia evoked by i.c.v.-oseltamivir is inhibited by non-selective dopamine receptor antagonists ...
Akihiro Fukushima, Arisa Fukui, Yuki Takemura, Yasuhiro Maeda, Hideki Ono   +4 more
doaj   +1 more source